InvestorsHub Logo
Followers 32
Posts 2793
Boards Moderated 3
Alias Born 10/24/2015

Re: NY1972 post# 172

Friday, 10/07/2022 2:41:59 PM

Friday, October 07, 2022 2:41:59 PM

Post# of 381
From FB https://www.fiercebiotech.com/biotech/allogene-gets-green-light-pivotal-car-t-trial-starts-industrys-first-shelf-phase-2

CRSP is continuing to enroll and dose patients in the pivotal trial of CTX110 (I think they are testing a consolidation dose as well). Also, at ASH 2023 they should have some initial data on CTX112, a next-gen version.

In addition, FATE will host a webcast either at ASH or early next year and give more details on the path forward for FT516/596.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent FATE News